GlassScriptPhysician profile
Kimberly A Funches Jackson
NPI 1497705123
$1,636.17
in general payments reported to CMS, 2019-2025
23 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $48.35 · 2021: $267 · 2022: $200 · 2023: $293 · 2024: $160 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.62 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $150.06 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $140.84 | 2025 | Voquezna |
| Abbvie INC. | $139.55 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.86 | 2021-2023 | |
| Novo Nordisk INC | $110.71 | 2019-2025 | Wegovy |
| Pfizer INC. | $73.20 | 2019-2020 | |
| Genzyme Corporation | $54.95 | 2023 | |
| Esperion Therapeutics, INC. | $53.29 | 2021-2022 | |
| Lilly USA, LLC | $52.98 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Verona Pharma, INC. | $52.61 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $49.08 | 2025 | |
| Exact Sciences Corporation | $37.11 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $35.26 | 2021-2024 | |
| Horizon Therapeutics Plc | $22.87 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.11 | 2025 | Capvaxive, Gardasil 9 |
| Circassia INC. | $18.56 | 2019 | |
| Astellas Pharma US INC | $17.09 | 2024 | Veozah |
| Amgen INC. | $15.75 | 2022 | |
| Amarin Pharma, INC. | $15.25 | 2020 | |
| Sumitomo Pharma America, INC. | $15.23 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $14.49 | 2019 | |
| Aytu Biopharma, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Funches Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.